Skip to main content
SpringerLink
Log in

Tetanus and Pertussis vaccines: their usefulness in the aging population

  • Review Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Immunization is a safe, effective and simple way of preventing life-threatening tetanus infection in children and adults, and is therefore recommended for all age groups in all European countries. In older persons, despite waning immunity with increasing age, the majority of vaccinees attain protective tetanus immunity under a proper vaccination schedule. Based on the scientific evidence, decennial boosters are recommended for elderly persons who have received primary tetanus vaccination in the past. Until recently, pertussis vaccination was understood as an early childhood intervention. Due to decreasing immunity, re-vaccination of youngsters and adults is recommended and is also considered for seniors 60 years and over. Routine immunization of seniors against pertussis every ten years yields a high level of protection of older individuals, and at the same time contributes to epidemiological control of pertussis in the population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dundar V, Ymuk Z, Ozturk-Dundar D, Erdogan S, Gacar GJ. Prevalence of tetanus immunity in the Kocaeli region, Turkey. Jpn J Infect Dis 2005; 58: 279–82.

    PubMed  Google Scholar 

  2. Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance: United States, 1998–2000. Morb Mortal Wkly Rep Surveill Summ 2003; 52: 1–8.

    Google Scholar 

  3. de Melker HE, van den Hof S, Berbers GA, Nagelkerke NJD, Rümke HC, Conyn-van Spaendonck MA. A population-based study on tetanus antitoxin levels in the Netherlands. Vaccine 2000; 18: 100–8.

    Article  Google Scholar 

  4. de Melker HE, van den Hof S, Berbers GA, Conyn-van Spaendonck MA. Evaluation of the national immunization program in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. Vaccine 2003; 21: 716–20.

    Article  PubMed  Google Scholar 

  5. Kretsinger K, Broder KR, Cortese MM et al; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acelter lular pertussis vaccine, recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55: 1–37.

    Google Scholar 

  6. Maclennan R, Schofield FD, Pittman M, Hardegree MC, Barile MF. Immunization against neonatal tetanus in New Guinea: antitoxin response of pregnant women to adjuvant and plain toxoids. Bull World Health Organ 1965; 32: 683–97.

    PubMed  CAS  Google Scholar 

  7. Björkholm B, Hagberg L, Sundbeck G, Granström M. Booster effect of low doses of tetanus toxoid in elderly vaccinees. Eur J Clin Microbiol Infect Dis 2000; 19: 195–9.

    Article  PubMed  Google Scholar 

  8. Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995; 332: 761–6.

    Article  PubMed  CAS  Google Scholar 

  9. McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136: 660–6.

    Article  PubMed  Google Scholar 

  10. Dominguez A, Plans P, Costa J et al. The seroepidemiology of tetanus in Catalonia, Spain. Med Microbiol Immunol 2007; 196: 115–9.

    Article  PubMed  CAS  Google Scholar 

  11. Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005; 23: 3232–5.

    Article  PubMed  Google Scholar 

  12. Kaml M, Weiskirchner I, Keller M et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006; 24: 6808–11.

    Article  PubMed  CAS  Google Scholar 

  13. Maple PAC, Jones CS, Wall EC et al. Immunity to diphtheria and tetanus in England and Wales. Vaccine 2000; 19: 167–73.

    Article  PubMed  CAS  Google Scholar 

  14. Walory J, Grzesiowski P, Hryniewicz W. Immunity against diphtheria and tetanus in the adult Polish population. Pol Merkur Lekarski 2000; 9: 687–92.

    PubMed  CAS  Google Scholar 

  15. Fordymacka A. Immunity against diphtheria and tetanus in various age groups after 40 years since implementation of the mass vaccination program. Przegl Epidemiol 2000; 54: 333–41.

    PubMed  CAS  Google Scholar 

  16. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006; 55 (No. RR-15).

  17. Pichichero ME, Rennels MB, Edwards KM et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293: 3003–11.

    Article  PubMed  CAS  Google Scholar 

  18. Simonsen O, Badsberg JH, Kjeldsen K et al. The fall-off in serum concentration of tetanus antitoxin after primary and booster vaccination. Acta Pathol Microbiol Scand 1985; 94: 77–82.

    Google Scholar 

  19. Janout V, Matouskova I, Machova L, Cizek L, Janoutova G, Hoskova J. Protection against tetanus in the aged people in the Czech Republic. A cross-sectional study. Arch Gerontol Geriatr 2005; 40: 123–8.

    Article  Google Scholar 

  20. Wassilak SGF, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In Plotkin S, Orenstein W, Offit P, eds. Vaccines. 5th ed. Saunders Elsevier, 2008.

  21. Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 1998; 16: 1016–23.

    Article  PubMed  CAS  Google Scholar 

  22. Lloyd JC, Haber P, Mootrey GT, Braun MM, Rhodes PH, Chen RT. Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS), 1991–1997. Vaccine 2003; 21: 3746–50.

    Article  PubMed  Google Scholar 

  23. CDC. Percentage of persons aged ≥18 years who reported receiving influenza or pneumococcal vaccine or tetanus toxoid, by age and selected characteristics — National Health Interview Survey, United States, 1999. Available at http://www.cdc.gov/nip/coverage/NHIS/tables/general-99.pdf. Accessed February 28, 2009.

  24. CDC. Record of the Meeting of the Advisory Committee on Immunization Practices, October 26–27, 2005. Available at http://www.cdc.gov/nip/ACIP/minutes/acip-min-oct05.pdf. Accessed February 28, 2009.

  25. Scott J, Hickey J. Immunizing adults against tetanus and diphtheria. Can Fam Physician 2003; 49: 587–8.

    PubMed  Google Scholar 

  26. Bartošovič I, Krajčík Š, Hegyi L. Vaccination of social care facility residents agains influenza and tetanus (in Slovak). Geriatria 2001; 7: 164–8.

    Google Scholar 

  27. Edwards KM Decker MD. Pertussis vaccines. In Plotkin S, Orenstein W, Offit P, eds. Vaccines. 5th ed. Saunders Elsevier, 2008.

  28. Kerr J, Matthews R. Bordetella pertussis infection: Pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Microbiol Infect Dis 2000; 19: 77–88.

    Article  PubMed  CAS  Google Scholar 

  29. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 2007; 26: 806–10.

    Article  PubMed  Google Scholar 

  30. de Melker HE, Schellekens JF, Neppelenbroek SE, Mool FR, Rumke HS, Conyn-van Soaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands, observation on surveillance data. Emerg Infect Dis 2000; 6: 348–57.

    Article  PubMed  Google Scholar 

  31. Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995–2005 — trends by region and age group. Commun Dis Intell 2007; 31: 205–15.

    Google Scholar 

  32. Halperin SA. The control of pertussis 2007 and beyond. N Engl J Med 2007; 356: 110–3.

    Article  PubMed  CAS  Google Scholar 

  33. Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002; 2: 744–50.

    Article  Google Scholar 

  34. Robbins JB, Schneerson R, Trollfors B et al. The diphteria and pertussis components of diphteria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis 2005; 191: 81–8.

    Article  PubMed  Google Scholar 

  35. CDC: Pertussis — United States, 2001–2003. Morb Mortal Wkly Rep 2005; 54: 1283–6.

    Google Scholar 

  36. Conference report: International Bordetella pertussis assay, standardization and harmonization meeting report. Center for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007. Vaccine 2009; 27: 803–14.

  37. Hu JJ, Lu CY, Chang LY et al. Survey of pertussis in patients with prolonged cough. J Microbiol Immunol Infect 2006; 39: 54–8.

    PubMed  Google Scholar 

  38. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by healthcare personnel. Morb Mortal Wkly Rep 2006; 55: 1–3.

    Google Scholar 

  39. McIntyre PB, Burgess MA, Egan A, Schuerman L, Hoet B. Booster vaccination of adults with reduced-antigen-content diphteria, tetanus and pertussis vaccine: immunogenicity 5 years post vaccination. Vaccine 2009; 27: 1062–6.

    Article  PubMed  CAS  Google Scholar 

  40. Cortese MM, Baughman AL, Brown K, Srivastava P. A “new age” in pertussis prevention: new opportunities through adult vaccination. Am J Prev Med 2007; 32: 177–85.

    Article  PubMed  Google Scholar 

  41. Keitel W. Cellular and acellular pertussis vaccines in adults. Clin Infect Dis 1999; 28 (Suppl 2): S118–23.

    Article  PubMed  Google Scholar 

  42. Rothstein E, Anderson E, Decker M, Poland G, Reisinger K, Langerberg A. An observer-blinded, randomised, placebo-controlled study of the safety and immunogenecity of an acellular pertussis vaccine (aP) in healthy adults (abstract G-29) In Abstracts of the 38th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). ASM, Washington, 1998.

  43. Shefer A, Dales L, Nelson M, Werner B, Baron R, Jackson R. Use and safety of acellular pertussis vaccine among adult hospital staff during an outbreak of pertussis. J Infect Dis 1995; 171: 1053–6.

    Article  PubMed  CAS  Google Scholar 

  44. Edelman K, He Q, Makinen J et al. Immunity to pertussis after booster immunization during adolescence. Clin Infect Dis 2007; 44: 1271–7.

    Article  PubMed  CAS  Google Scholar 

  45. Le T, Cherry JD, Chang SJ et al. Immune response and antibody decay after immunization of adolescents and adults with acellular pertussis vaccine: the APERT Study. J Infect Dis 2004; 190: 535–44.

    Article  PubMed  CAS  Google Scholar 

  46. Coudeville L, van Rie A, Andre P. Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect 2008; 136: 604–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Geriatrics, First Faculty of Medicine, Charles University, Londynska 15, Prague 2, 120 00, Czech Republic

    Eva Topinkovà MD, PhD

  2. Department of Infectious Diseases, 2nd Faculty of Medicine, Charles University in Prague, Czech Republic

    Vilma Marešovà

Authors
  1. Eva Topinkovà MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vilma Marešovà
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva Topinkovà MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Topinkovà, E., Marešovà, V. Tetanus and Pertussis vaccines: their usefulness in the aging population. Aging Clin Exp Res 21, 229–235 (2009). https://doi.org/10.1007/BF03324910

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03324910

Keywords

Search

Navigation